FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2046566499> ?p ?o ?g. }

• W2046566499 endingPage "1686" @default.
• W2046566499 startingPage "1670" @default.
• W2046566499 abstract "Hypercholesterolemic patients with metabolic syndrome (MS) are at high risk for coronary heart disease. The National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) guidelines provide the option of aggressively lowering low-density lipoprotein cholesterol (LDL-C) in hypercholesterolemic patients with MS.The lipid-modifying efficacy of simvastatin and atorvastatin in hypercholesterolemic patients with MS as defined by NCEP ATP III was assessed.A post hoc subgroup analysis was performed on data from a 36-week, multicenter (54 sites worldwide), randomized, double-blind, parallel-group, dose-escalation (forced-titration) study designed to assess the effects of simvastatin (40-80 mg) and atorvastatin (20-80 mg) on high-density lipoprotein cholesterol (HDL-C) and apolipoprotein (apo) A-I levels in patients with LDL-C > or = 160 mg/dL. Patients were classified as having MS if they met >/=3 of the following criteria: (1) triglyceride (TG) level > or =150 mg/dL; (2) HDL-C <40 mg/dL (men) or <50 mg/dL (women); (3) secondary diagnosis of type 2 diabetes mellitus and/or taking antidiabetic medication and/or fasting serum glucose (FSG) level > or =110 mg/dL; (4) secondary diagnosis of hypertension and/or taking antihypertensive medication and/or systolic blood pressure (SBP)/diastolic blood pressure (DBP) > or =130/ > or =85 mm Hg; and (5) body mass index (BMI) > or =30 kg/m(2) (surrogate for waist circumference).Of 808 evaluable patients, 212 (26.2%) were classified as having MS at baseline. Compared with the non-MS subgroup, MS patients were slightly older and more likely to be female. They also had higher BMI, SBP/DBP, FSG, and TG levels, and lower HDL-C and apo A-I levels than non-MS patients. The simvastatin group contained 99 patients; the atorvastatin group, 113 patients. Both drugs produced large reductions in total cholesterol, LDL-C, non-HDL-C, TG, and apo B, with atorvastatin producing slightly greater reductions in TG. However, simvastatin consistently produced larger increases in HDL-C and apo A-I than atorvastatin, especially at higher doses. After 36 weeks of treatment, 47.7% and 48.5% in the simvastatin and atorvastatin groups, respectively, no longer met > or =3 of the MS criteria.In hypercholesterolemic patients with characteristics of MS, simvastatin and atorvastatin had comparable beneficial effects on apo B-containing atherogenic lipids and lipoproteins, and MS status was effectively modified by both drugs. However, although atorvastatin produced slightly larger decreases in TG, simvastatin produced larger increases in HDL-C." @default.
• W2046566499 created "2016-06-24" @default.
• W2046566499 creator A5010300943 @default.
• W2046566499 creator A5014081492 @default.
• W2046566499 creator A5041403685 @default.
• W2046566499 creator A5052604218 @default.
• W2046566499 creator A5067906247 @default.
• W2046566499 creator A5081512523 @default.
• W2046566499 date "2003-06-01" @default.
• W2046566499 modified "2023-10-16" @default.
• W2046566499 title "Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome" @default.
• W2046566499 cites W1905082515 @default.
• W2046566499 cites W2001577103 @default.
• W2046566499 cites W2005516314 @default.
• W2046566499 cites W2030357298 @default.
• W2046566499 cites W2043180355 @default.
• W2046566499 cites W2052740563 @default.
• W2046566499 cites W2064707131 @default.
• W2046566499 cites W2066051121 @default.
• W2046566499 cites W2067310352 @default.
• W2046566499 cites W2078807483 @default.
• W2046566499 cites W2134815288 @default.
• W2046566499 cites W2145167597 @default.
• W2046566499 cites W2146322658 @default.
• W2046566499 cites W2152086330 @default.
• W2046566499 cites W2154159535 @default.
• W2046566499 cites W2155481867 @default.
• W2046566499 cites W2156857720 @default.
• W2046566499 cites W4238251256 @default.
• W2046566499 cites W4244556595 @default.
• W2046566499 cites W4249825849 @default.
• W2046566499 cites W4252910375 @default.
• W2046566499 cites W4254869113 @default.
• W2046566499 doi "https://doi.org/10.1016/s0149-2918(03)80162-5" @default.
• W2046566499 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12860491" @default.
• W2046566499 hasPublicationYear "2003" @default.
• W2046566499 type Work @default.
• W2046566499 sameAs 2046566499 @default.
• W2046566499 citedByCount "36" @default.
• W2046566499 countsByYear W20465664992012 @default.
• W2046566499 countsByYear W20465664992013 @default.
• W2046566499 countsByYear W20465664992015 @default.
• W2046566499 countsByYear W20465664992016 @default.
• W2046566499 countsByYear W20465664992017 @default.
• W2046566499 countsByYear W20465664992022 @default.
• W2046566499 crossrefType "journal-article" @default.
• W2046566499 hasAuthorship W2046566499A5010300943 @default.
• W2046566499 hasAuthorship W2046566499A5014081492 @default.
• W2046566499 hasAuthorship W2046566499A5041403685 @default.
• W2046566499 hasAuthorship W2046566499A5052604218 @default.
• W2046566499 hasAuthorship W2046566499A5067906247 @default.
• W2046566499 hasAuthorship W2046566499A5081512523 @default.
• W2046566499 hasConcept C126322002 @default.
• W2046566499 hasConcept C134018914 @default.
• W2046566499 hasConcept C164705383 @default.
• W2046566499 hasConcept C2776329913 @default.
• W2046566499 hasConcept C2777482532 @default.
• W2046566499 hasConcept C2778163477 @default.
• W2046566499 hasConcept C2778402494 @default.
• W2046566499 hasConcept C2778913445 @default.
• W2046566499 hasConcept C2780221984 @default.
• W2046566499 hasConcept C2780578515 @default.
• W2046566499 hasConcept C511355011 @default.
• W2046566499 hasConcept C555293320 @default.
• W2046566499 hasConcept C62746215 @default.
• W2046566499 hasConcept C71924100 @default.
• W2046566499 hasConcept C84393581 @default.
• W2046566499 hasConcept C90924648 @default.
• W2046566499 hasConceptScore W2046566499C126322002 @default.
• W2046566499 hasConceptScore W2046566499C134018914 @default.
• W2046566499 hasConceptScore W2046566499C164705383 @default.
• W2046566499 hasConceptScore W2046566499C2776329913 @default.
• W2046566499 hasConceptScore W2046566499C2777482532 @default.
• W2046566499 hasConceptScore W2046566499C2778163477 @default.
• W2046566499 hasConceptScore W2046566499C2778402494 @default.
• W2046566499 hasConceptScore W2046566499C2778913445 @default.
• W2046566499 hasConceptScore W2046566499C2780221984 @default.
• W2046566499 hasConceptScore W2046566499C2780578515 @default.
• W2046566499 hasConceptScore W2046566499C511355011 @default.
• W2046566499 hasConceptScore W2046566499C555293320 @default.
• W2046566499 hasConceptScore W2046566499C62746215 @default.
• W2046566499 hasConceptScore W2046566499C71924100 @default.
• W2046566499 hasConceptScore W2046566499C84393581 @default.
• W2046566499 hasConceptScore W2046566499C90924648 @default.
• W2046566499 hasIssue "6" @default.
• W2046566499 hasLocation W20465664991 @default.
• W2046566499 hasLocation W20465664992 @default.
• W2046566499 hasOpenAccess W2046566499 @default.
• W2046566499 hasPrimaryLocation W20465664991 @default.
• W2046566499 hasRelatedWork W2005673910 @default.
• W2046566499 hasRelatedWork W2042818572 @default.
• W2046566499 hasRelatedWork W2054761025 @default.
• W2046566499 hasRelatedWork W2055835176 @default.
• W2046566499 hasRelatedWork W2064285183 @default.
• W2046566499 hasRelatedWork W2105745518 @default.
• W2046566499 hasRelatedWork W2155947160 @default.
• W2046566499 hasRelatedWork W2170635270 @default.
• W2046566499 hasRelatedWork W2523752433 @default.

• next